Literature DB >> 29599290

TGFβ and IGF1R signaling activates protein kinase A through differential regulation of ezrin phosphorylation in colon cancer cells.

Premila D Leiphrakpam1, Michael G Brattain2, Jennifer D Black3, Jing Wang4.   

Abstract

Aberrant cell survival plays a critical role in cancer progression and metastasis. We have previously shown that ezrin, a cAMP-dependent protein kinase A-anchoring protein (AKAP), is up-regulated in colorectal cancer (CRC) liver metastasis. Phosphorylation of ezrin at Thr-567 activates ezrin and plays an important role in CRC cell survival associated with XIAP and survivin up-regulation. In this study, we demonstrate that in FET and GEO colon cancer cells, knockdown of ezrin expression or inhibition of ezrin phosphorylation at Thr-567 increases apoptosis through protein kinase A (PKA) activation in a cAMP-independent manner. Transforming growth factor (TGF) β signaling inhibits ezrin phosphorylation in a Smad3-dependent and Smad2-independent manner and regulates pro-apoptotic function through ezrin-mediated PKA activation. On the other hand, ezrin phosphorylation at Thr-567 by insulin-like growth factor 1 receptor (IGF1R) signaling leads to cAMP-dependent PKA activation and enhances cell survival. Further studies indicate that phosphorylated ezrin forms a complex with PKA RII, and dephosphorylated ezrin dissociates from the complex and facilitates the association of PKA RII with AKAP149, both of which activate PKA yet lead to either cell survival or apoptosis. Thus, our studies reveal a novel mechanism of differential PKA activation mediated by TGFβ and IGF1R signaling through regulation of ezrin phosphorylation in CRC, resulting in different cell fates. This is of significance because TGFβ and IGF1R signaling pathways are well-characterized tumor suppressor and oncogenic pathways, respectively, with important roles in CRC tumorigenesis and metastasis. Our studies indicate that they cross-talk and antagonize each other's function through regulation of ezrin activation. Therefore, ezrin may be a potential therapeutic target in CRC.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  A-kinase anchoring protein (AKAP); IGF1R; Smad3; X-linked inhibitor of apoptosis protein (XIAP); apoptosis; colon cancer; ezrin; metastasis; survivin; transforming growth factor beta (TGF-β)

Mesh:

Substances:

Year:  2018        PMID: 29599290      PMCID: PMC5971434          DOI: 10.1074/jbc.RA117.001299

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.

Authors:  Stefania Napolitano; Giulia Martini; Barbara Rinaldi; Erika Martinelli; Maria Donniacuo; Liberato Berrino; Donata Vitagliano; Floriana Morgillo; Giusy Barra; Raffaele De Palma; Francesco Merolla; Fortunato Ciardiello; Teresa Troiani
Journal:  Clin Cancer Res       Date:  2015-04-02       Impact factor: 12.531

Review 2.  AKAP signalling complexes: focal points in space and time.

Authors:  Wei Wong; John D Scott
Journal:  Nat Rev Mol Cell Biol       Date:  2004-12       Impact factor: 94.444

3.  Akt2 phosphorylates ezrin to trigger NHE3 translocation and activation.

Authors:  Harn Shiue; Mark W Musch; Yingmin Wang; Eugene B Chang; Jerrold R Turner
Journal:  J Biol Chem       Date:  2004-11-04       Impact factor: 5.157

4.  Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection.

Authors:  Takehiko Dohi; Fang Xia; Dario C Altieri
Journal:  Mol Cell       Date:  2007-07-06       Impact factor: 17.970

5.  Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells.

Authors:  G Bulut; S-H Hong; K Chen; E M Beauchamp; S Rahim; G W Kosturko; E Glasgow; S Dakshanamurthy; H-S Lee; I Daar; J A Toretsky; C Khanna; A Uren
Journal:  Oncogene       Date:  2011-06-27       Impact factor: 9.867

6.  Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells.

Authors:  J Wang; W Han; E Zborowska; J Liang; X Wang; J K Willson; L Sun; M G Brattain
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

Review 7.  Heterogeneity of human colon carcinoma.

Authors:  M G Brattain; A E Levine; S Chakrabarty; L C Yeoman; J K Willson; B Long
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

8.  The percentage of CD133+ cells in human colorectal cancer cell lines is influenced by Mycoplasma hyorhinis infection.

Authors:  Elisabetta Mariotti; Marica Gemei; Peppino Mirabelli; Francesca D'Alessio; Rosa Di Noto; Giuliana Fortunato; Luigi Del Vecchio
Journal:  BMC Cancer       Date:  2010-03-30       Impact factor: 4.430

9.  A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites.

Authors:  N Sato; N Funayama; A Nagafuchi; S Yonemura; S Tsukita; S Tsukita
Journal:  J Cell Sci       Date:  1992-09       Impact factor: 5.285

10.  Differential PKA activation and AKAP association determines cell fate in cancer cells.

Authors:  Erik D Hedrick; Ekta Agarwal; Premila D Leiphrakpam; Katie L Haferbier; Michael G Brattain; Sanjib Chowdhury
Journal:  J Mol Signal       Date:  2013-10-01
View more
  7 in total

1.  Prognostic and therapeutic implications of NHERF1 expression and regulation in colorectal cancer.

Authors:  Premila D Leiphrakpam; Audrey J Lazenby; Sanjib Chowdhury; Lynette M Smith; Michelle Mathiesen; Michael G Brattain; Jing Wang; Jennifer D Black; Chandrakanth Are
Journal:  J Surg Oncol       Date:  2019-12-22       Impact factor: 3.454

2.  High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy.

Authors:  I-Ping Yang; Zhi-Feng Miao; Ching-Wen Huang; Hsiang-Lin Tsai; Yung-Sung Yeh; Wei-Chih Su; Tsung-Kun Chang; Se-Fen Chang; Jaw-Yuan Wang
Journal:  Ther Adv Med Oncol       Date:  2019-08-20       Impact factor: 8.168

3.  Colon Cancer-Related Genes Identification and Function Study Based on Single-Cell Multi-Omics Integration.

Authors:  Xuepu Sun; Yu Guo; Yu Zhang; Peng Zhao; Zhaoqing Wang; Zheng Wei; Haiquan Qiao
Journal:  Front Cell Dev Biol       Date:  2021-11-25

Review 4.  Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics.

Authors:  Neerada Meenakshi Warrier; Prasoon Agarwal; Praveen Kumar
Journal:  Stem Cell Rev Rep       Date:  2020-10       Impact factor: 5.739

5.  GDF11 enhances therapeutic efficacy of mesenchymal stem cells for myocardial infarction via YME1L-mediated OPA1 processing.

Authors:  Yun Zhao; Jinyun Zhu; Ning Zhang; Qi Liu; Yingchao Wang; Xinyang Hu; Jinghai Chen; Wei Zhu; Hong Yu
Journal:  Stem Cells Transl Med       Date:  2020-06-09       Impact factor: 6.940

6.  The Collagen-Modifying Enzyme PLOD2 Is Induced and Required during L1-Mediated Colon Cancer Progression.

Authors:  Sanith Cheriyamundath; Anmol Kumar; Nancy Gavert; Thomas Brabletz; Avri Ben-Ze'ev
Journal:  Int J Mol Sci       Date:  2021-03-29       Impact factor: 5.923

7.  Correlation of PRL3 expression with colorectal cancer progression.

Authors:  Premila D Leiphrakpam; Audrey J Lazenby; Lynette M Smith; Michael G Brattain; Jennifer D Black; Jing Wang; Chandrakanth Are
Journal:  J Surg Oncol       Date:  2020-11-12       Impact factor: 3.454

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.